Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $0.29 on Tuesday. The firm has a market cap of $16.01 million, a price-to-earnings ratio of -0.14 and a beta of 0.68. The company has a 50 day moving average price of $0.29 and a 200-day moving average price of $0.42. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.40.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The firm had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. On average, sell-side analysts anticipate that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new stake in Cara Therapeutics, Inc. (NASDAQ:CARA) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned approximately 0.17% of Cara Therapeutics at the end of the most recent reporting period. 44.66% of the stock is owned by institutional investors and hedge funds.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.